[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100594490":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":11,"centralContacts":25,"locations":31,"responsibleParty":172,"collaborators":11,"id":174,"slug":11,"hasResults":175,"nctId":176,"briefTitle":177,"officialTitle":178,"acronym":11,"eligibilityCriteria":179,"healthyVolunteers":175,"sex":180,"minAge":181,"maxAge":11,"enrollmentInfo":182,"targetDuration":11,"studyType":185,"phases":186,"briefSummary":188,"conditions":189,"keywords":11,"overallStatus":34,"whyStopped":11,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":205,"locationsCount":206},{"fullName":5,"class":6},"Aktis Oncology, Inc.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"[225Ac]Ac-AKY-1189","EXPERIMENTAL",null,[13,14],"Drug: [225Ac]Ac-AKY-1189 (therapeutic)","Drug: [64Cu]Cu-AKY-1189 (imaging)",[16,21],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":11},"DRUG","[225Ac]Ac-AKY-1189 (therapeutic)","\\[225Ac\\]Ac-AKY-1189 Injection",[9],{"type":17,"name":22,"description":23,"armGroupLabels":24,"otherNames":11},"[64Cu]Cu-AKY-1189 (imaging)","\\[64Cu\\]Cu-AKY-1189 Injection",[9],[26],{"name":27,"role":28,"phone":29,"phoneExt":11,"email":30},"Janet Horton, MD","CONTACT","978-208-3986","AKY-1189-01inquiries@aktisoncology.com",[32,50,64,79,96,111,125,142,157],{"facility":33,"status":34,"city":35,"state":36,"zip":37,"country":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"City of Hope","RECRUITING","Duarte","California","91010","United States",{"type":40,"coordinates":41},"Point",[42,43],-117.97729,34.13945,{"lat":43,"lon":42},[46],{"name":47,"role":28,"phone":48,"phoneExt":11,"email":49},"Abhishek Tripathi, MD","626-256-4673","atripathi@coh.org",{"facility":51,"status":34,"city":52,"state":36,"zip":53,"country":38,"cosmosGeoPoint":54,"geoPoint":58,"contacts":59},"Hoag Memorial Hospital Presbyterian","Irvine","92618",{"type":40,"coordinates":55},[56,57],-117.82311,33.66946,{"lat":57,"lon":56},[60],{"name":61,"role":28,"phone":62,"phoneExt":11,"email":63},"Ryan Reddy, MD","949-764-4577","ryan.reddy@hoag.org",{"facility":65,"status":34,"city":66,"state":67,"zip":68,"country":38,"cosmosGeoPoint":69,"geoPoint":73,"contacts":74},"Biogenix Molecular, LLC","Miami","Florida","33165",{"type":40,"coordinates":70},[71,72],-80.19366,25.77427,{"lat":72,"lon":71},[75],{"name":76,"role":28,"phone":77,"phoneExt":11,"email":78},"Jerry Joseph","786-791-1799","jjoseph@cira-health.com",{"facility":80,"status":34,"city":81,"state":82,"zip":83,"country":38,"cosmosGeoPoint":84,"geoPoint":88,"contacts":89},"University of Iowa","Iowa City","Iowa","52242",{"type":40,"coordinates":85},[86,87],-91.53017,41.66113,{"lat":87,"lon":86},[90,94],{"name":91,"role":28,"phone":92,"phoneExt":11,"email":93},"Kristin West","319-356-3656","kristin-gaimari-varner@uiowa.edu",{"name":95,"role":28,"phone":11,"phoneExt":11,"email":11},"Kristin Plichta, MD, PhD",{"facility":97,"status":34,"city":98,"state":99,"zip":100,"country":38,"cosmosGeoPoint":101,"geoPoint":105,"contacts":106},"United Theranostics","Glen Burnie","Maryland","21061",{"type":40,"coordinates":102},[103,104],-76.62469,39.16261,{"lat":104,"lon":103},[107],{"name":108,"role":28,"phone":109,"phoneExt":11,"email":110},"Amanda Huggins","667-467-3669","clinicaltrial@unithera.com",{"facility":112,"status":34,"city":113,"state":114,"zip":115,"country":38,"cosmosGeoPoint":116,"geoPoint":120,"contacts":121},"BAMF Health","Grand Rapids","Michigan","49503",{"type":40,"coordinates":117},[118,119],-85.66809,42.96336,{"lat":119,"lon":118},[122],{"name":11,"role":28,"phone":123,"phoneExt":11,"email":124},"616-330-2735","ResearchClinicalTeam@bamfhealth.com",{"facility":126,"status":34,"city":127,"state":127,"zip":128,"country":38,"cosmosGeoPoint":129,"geoPoint":133,"contacts":134},"Icahn School of Medicine at Mt. Sinai","New York","10029",{"type":40,"coordinates":130},[131,132],-74.00597,40.71427,{"lat":132,"lon":131},[135,139],{"name":136,"role":28,"phone":137,"phoneExt":11,"email":138},"Sophia Rhoads","317-903-4419","Sophia.rhoads@mssm.edu",{"name":140,"role":28,"phone":11,"phoneExt":11,"email":141},"Patricia Acon","patricia.acon@mssm.edu",{"facility":143,"status":34,"city":144,"state":145,"zip":146,"country":38,"cosmosGeoPoint":147,"geoPoint":151,"contacts":152},"UPMC","Pittsburgh","Pennsylvania","15232",{"type":40,"coordinates":148},[149,150],-79.99589,40.44062,{"lat":150,"lon":149},[153],{"name":154,"role":28,"phone":155,"phoneExt":11,"email":156},"Samantha Demko, RN, BSN","412-623-1400","albesl@upmc.edu",{"facility":158,"status":34,"city":159,"state":160,"zip":161,"country":38,"cosmosGeoPoint":162,"geoPoint":166,"contacts":167},"MD Anderson Cancer Center","Houston","Texas","77030",{"type":40,"coordinates":163},[164,165],-95.36327,29.76328,{"lat":165,"lon":164},[168],{"name":169,"role":28,"phone":170,"phoneExt":11,"email":171},"Natalie Velez","713-792-1478","navelez@mdanderson.org",{"type":173,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100594490",false,"NCT07020117","A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors","NECTINIUM-2: A Phase 1b, 2 Part, Multicenter, Single Arm, Open Label Study to Evaluate the Safety and Efficacy of a Nectin-4 Radiopharmaceutical ([225Ac]Ac-AKY-1189) in Patients With Previously Treated Locally Advanced or Metastatic Solid Tumors","Inclusion Criteria:\n\n* Histologic or cytologic confirmation of locally advance or metastatic disease\n* Radiologic confirmation on CT of at least one measurable tumor lesion per RECIST v1.1\n* ECOG Performance Status of 0 or 1\n* Adequate end-organ function\n* Ability to give informed consent and comply with study requirements\n* Patients with CNS metastases are eligible if they have received therapy and are neurologically stable, asymptomatic and not receiving corticosteroids\n* Documented disease progression on prior line of therapy for metastatic disease\n\nExclusion Criteria:\n\n* Prior treatment with a therapeutic radiopharmaceutical\n* Prior treatment with a Nectin-4 targeted therapy, except enfortumab vedotin\n* Received an investigational agent within the previous 28days\n* Prior treatment with a cytotoxic chemotherapy, targeted therapy, biologic agent, immunotherapy or external-beam radiotherapy in the 3 weeks prior to study treatment\n* Concurrent serious medical condition that would impair study participation or impact the assessment of treatment related toxicity","ALL","18 Years",{"count":183,"type":184},150,"ESTIMATED","INTERVENTIONAL",[187],"PHASE1","This is a first-in-human Phase 1b, 2-part, multicenter open-label clinical study to evaluate safety and efficacy of a Nectin-4 radiopharmaceutical (\\[225Ac\\]Ac-AKY-1189) in patients with locally advanced or metastatic solid tumors and to establish the maximum tolerated dose (MTD) or maximum administered dose (MAD) and the recommended Phase 2 dose.",[190,191,192,193,194,195,196],"Urothelial Carcinoma Bladder","Triple Negative Breast Cancer (TNBC)","Hormone Receptor Positive Breast Adenocarcinoma","Non Small Cell Lung Cancer","Cervical Adenocarcinoma","Colorectal Adenocarcinoma","Head and Neck Cancer","2026-04-17",{"date":199,"type":200},"2026-04-21","ACTUAL",{"date":202,"type":200},"2025-08-22",{"date":204,"type":184},"2032-06",{"name":5,"class":6},9]